Key points from article :
NewLimit, a longevity-focused biotech company, has raised $130 million in Series B funding to advance its epigenetic reprogramming platform. This significant investment supports NewLimit’s mission to extend human healthspan by targeting ageing as the root cause of diseases. The company has made breakthroughs in epigenetic reprogramming, which involves manipulating the epigenome to reset gene activity patterns in aged cells. By rejuvenating immune and liver cells, NewLimit has shown promise in preclinical studies, with potential applications for age-related diseases.
Their approach uses advances in single-cell genomics, epigenetic editing, and artificial intelligence, focusing on the most promising therapeutic candidates to increase capital efficiency. The company’s work prioritizes the immune system and liver, and its efforts aim to create a new class of medicines capable of preventing or reversing age-related diseases. The $130 million funding round, led by Kleiner Perkins, will help accelerate NewLimit's development, following its earlier Series A raise of $40 million. The company’s long-term goal is to inspire broader interest in ageing therapeutics.
The study was not linked to a specific journal but provides insight into the ongoing advancements in longevity biotech.
